What is it about?

Evaluation of single 4.5 mg fixed-dose rasburicase in patients with tumor lysis syndrome.

Featured Image

Why is it important?

Provides an alternative dosing regimen with lower cost compared to FDA-approved dosing

Read the Original

This page is a summary of: Single 4.5 mg fixed-dose of rasburicase for hyperuricemia associated with tumor lysis syndrome, Journal of Oncology Pharmacy Practice, April 2016, SAGE Publications,
DOI: 10.1177/1078155216644975.
You can read the full text:

Read

Contributors

The following have contributed to this page